EUCTR2011-003478-98-GR进行中（未招募）1 期
A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects who previously participated in a prior Phase 3 Abbott HS study and:
- •Completed the study; or
- •Experienced a loss of response (LOR); or
- •Experienced Worsening or Absence of Improvement
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1. Prior treatment with any other anti-TNF therapy (e.g., infliximab, etanercept), or participation in an adalimumab trial other than a prior Phase 3 Abbott HS study.
- •2. Subject received any oral antibiotic treatment for HS within 28 days prior to the Baseline visit, except for antibiotics permitted in a prior Phase 3 Abbott HS study.
- •3. Subject received oral concomitant analgesics (including opioids) for HS-related pain within 14 days prior to the Baseline visit, except for permitted analgesics taken in the prior Phase 3 Abbott HS study.
研究者
相似试验
进行中（未招募）
1 期
A multicenter study of the safety and efficacy of adalimumab in subjectswith moderate to severe hidradenitis suppurativaHidradenitis SuppurativaEUCTR2011-003478-98-HUAbbott GmbH & Co. KG600
进行中（未招募）
1 期
A multicenter study of the safety and efficacy of adalimumab in subjectswith moderate to severe hidradenitis suppurativaHidradenitis SuppurativaMedDRA version: 17.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858EUCTR2011-003478-98-DEAbbVie Deutschland GmbH & Co. KG600
进行中（未招募）
1 期
A multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativaHidradenitis SuppurativaEUCTR2011-003478-98-SEAbbVie Deutschland GmbH & Co. KG600
已完成
3 期
A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis SuppurativaNL-OMON39701AbbVie BV30
进行中（未招募）
1 期
A multicenter study of the safety and efficacy of adalimumab in subjectswith moderate to severe hidradenitis suppurativaMedDRA version: 14.1Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858Hidradenitis SuppurativaEUCTR2011-003478-98-CZAbbVie Deutschland GmbH & Co. KG600